Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | REN | P00797 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045821 | 0.89 | CTSS (0.67) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL7324916 | 0.88 | CTSS (0.68) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL24102984 | 0.88 | CTSS (0.68) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL31107927 | 0.88 | CTSS (0.60) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL2948481 | 0.88 | PPARA (0.74) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL5249102 | 0.88 | PPARA (0.74) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL2948482 | 0.88 | PPARA (0.74) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL31107834 | 0.87 | CTSS (0.59) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL6043317 | 0.87 | PPARA (0.64) | CTSSPPARARENPPARGCTSK | |
| SCHEMBL6857159 | 0.87 | REN (0.68) | CTSSRENCTSKCTSLPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP1, MMP2, TNF | CTSS 122/4885PPARA 1388/4885REN 156/4885 |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | CTSS 111/4885PPARA 1284/4885REN 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.